The 2024 Tang Prize is awarded to three scientists for the development of GLP-1
The 2024 Tang Prize in Biopharmaceutical Science has cast a spotlight on GLP-1 receptor agonists, sparking a global race among pharmaceutical companies. TE-8105 of Immunwork, an ultra-long-acting GLP-1 drug, is set to initiate its Phase I clinical trial in Australia, promising significant potential for future development!
